2026-01-02 - Analysis Report
Okay, here's a comprehensive report on Intuitive Surgical (ISRG) based on the provided data, followed by a consolidated analysis.

**1) Return Rate Comparison & Alpha/Beta Analysis**

*   **Company Overview:** Intuitive Surgical Inc. designs, manufactures, and markets robotic surgical systems.
*   **ISRG Cumulative Return:** 80.65%
*   **S&P 500 (VOO) Cumulative Return:** 91.40%
*   **Divergence:** -24.4 (Relative Divergence: 29.2)

    *   **Analysis:** ISRG has underperformed the S&P 500 over the measured period.  The divergence of -24.4 means ISRG's cumulative return is 24.4 percentage points lower than the S&P 500.  The relative divergence of 29.2 suggests that the current divergence is near the lower end of its historical range.

*   **Alpha, Beta, CAGR, MDD Analysis:**

    | Year       | CAGR  | MDD    | Alpha   | Beta | Cap(B) |
    |------------|-------|--------|---------|------|--------|
    | 2016-2018  | 49.0% | 99.5% | 45.0%  | 1.2  | 57.2   |
    | 2017-2019  | 40.0% | 71.2% | 23.0%  | 1.4  | 70.6   |
    | 2018-2020  | -8.0% | 75.1% | -29.0% | 1.2  | 97.8   |
    | 2019-2021  | 26.0% | 65.1% | -17.0% | 1.2  | 128.8  |
    | 2020-2022  | -18.0% | 100.0% | -16.0% | 1.2  | 95.1   |
    | 2021-2023  | -12.0% | 100.0% | -13.0% | 1.4  | 120.9  |
    | 2022-2024  | 35.0% | 100.0% | 16.0%  | 1.3  | 187.1  |
    | 2023-2025  | 60.0% | 71.0% | -2.0%  | 1.2  | 203.0  |

    *   **Analysis:**
        *   **CAGR (Compound Annual Growth Rate):**  CAGR has fluctuated significantly over the periods, showing strong growth in some years but declines in others. Recent years (2020-2023) have seen negative CAGR.
        *   **MDD (Maximum Drawdown):**  MDD has been high, indicating substantial potential losses during certain periods.  Several periods show 100% MDD, which is concerning.
        *   **Alpha:** Alpha is mixed, with positive alpha during some periods (2016-2019, 2022-2024) indicating outperformance relative to its beta, but negative alpha in other periods (2018-2023, 2023-2025) suggesting underperformance.
        *   **Beta:**  Beta is consistently around 1.2-1.4, meaning the stock is more volatile than the S&P 500.
        *   **Cap(B):**  Market capitalization has generally increased over time, but there are periods of decrease (2020-2022).
        *   In summary, ISRG demonstrates high volatility and has struggled to consistently outperform its benchmark in recent periods.

**2) Recent Stock Price Fluctuations**

*   **Current Close Price:** 566.36
*   **Last Market Data:** price': 566.36, 'previousClose': 572.63, 'change': -1.09
*   **5-day SMA:** 573.87
*   **20-day SMA:** 565.81
*   **60-day SMA:** 538.15

    *   **Analysis:** The current price is below the 5-day SMA, slightly above the 20-day SMA, and significantly above the 60-day SMA.  The 5-day SMA is above the 20-day SMA. This suggests a recent downtrend, but with underlying strength as indicated by the 60-day SMA. The negative change from the previous close confirms the recent downward pressure.

**3) RSI, PPO, Divergence, & Expected Return**

*   **Market Risk Indicator (MRI):** 0.9 (High Investment Recommended)
*   **RSI:** 56.89
*   **PPO:** -0.11
*   **Hybrid Signal:** cash_0%_Buy 90% of cash (1 shares - Safe - MRI:0.80)
*   **Recent (20 days) relative divergence change:** -1.3 (단기하락 - Short-term decline)
*   **Expected Return (%):** 0.0

    *   **Analysis:**
        *   **MRI:** A high MRI of 0.9 suggests that the overall market is considered relatively stable.
        *   **RSI:** An RSI of 56.89 is neutral.
        *   **PPO:** A slightly negative PPO indicates that momentum is slightly downward.
        *   **Hybrid Signal:** The Hybrid Signal suggests a buy recommendation.
        *   **Recent Divergence Change:** The -1.3 indicates a recent decline in relative performance.
        *   **Expected Return:** The 0.0% expected return is a concern, suggesting no anticipated outperformance of the S&P 500 in the long term based on the current indicators.

**4) Recent News & Significant Events**

*   [2025-12-29] Intuitive Surgical Stock (ISRG) Opinions on 2025 Growth Guidance Update
*   [2025-12-13] Intuitive Surgical Stock Hits Key Support - Buying Opportunity?
*   [2026-01-01] Intuitive Surgical stock today: ISRG slips into 2026 as New Year’s Day shuts Wall Street
*   [2025-12-31] ISRG Stock Today (31 Dec 2025): Technical Indicators in Focus
*   [2025-12-08] ISRG Stock Forms Golden Crossover: Will the Uptrend Continue?
*   [2026-01-01] Roberts Wealth Advisors LLC Takes Position in Intuitive Surgical, Inc. $ISRG

    *   **Analysis:** The news is mixed. Some articles suggest buying opportunities based on support levels or technical patterns ("Golden Crossover"), while others reflect concerns about growth guidance and recent price declines. The "slipping into 2026" headline and the focus on technical indicators further suggest some uncertainty in the near term.

**4-2) Analyst Opinions**

*   **Mean Analyst Rating:**  - (No specific rating provided, but implies a relatively neutral stance)
*   **Number of Opinions:** 29
*   **Target Price:** 599.60 (Avg) / 700.00 (High) / 378.00 (Low)
*   **Recent Rating Changes:** Not provided.

    *   **Analysis:**  The analyst target price suggests a potential upside from the current price (566.36), but the wide range between the high and low targets (378.00 to 700.00) reflects considerable uncertainty in the stock's future performance.

**5) Recent Earnings Analysis**

| 날짜         | EPS  | 매출      |
|--------------|------|-----------|
| 2025-10-22   | 1.98 | 2.51 B$   |
| 2025-07-23   | 1.84 | 2.44 B$   |
| 2025-04-23   | 1.95 | 2.25 B$   |
| 2024-10-18   | 1.59 | 2.04 B$   |
| 2025-10-22   | 1.59 | 2.04 B$   |

*Note: the table contained a duplicated row*

    *   **Analysis:**  Both EPS (Earnings Per Share) and revenue have shown an increasing trend over the last few quarters. This indicates positive growth.

**6) Financial Information**

*   **Revenue and Profitability:**

| Quarter      | Revenue | Profit Margin |
|--------------|---------|---------------|
| 2025-09-30   | $2.51B  | 66.36%        |
| 2025-06-30   | $2.44B  | 66.31%        |
| 2025-03-31   | $2.25B  | 64.69%        |
| 2024-12-31   | $2.41B  | 68.04%        |
| 2024-09-30   | $2.04B  | 67.41%        |

    *   **Analysis:** Revenue shows a general upward trend, which aligns with the earnings analysis. Profit margins are consistently high, indicating strong profitability.

*   **Capital and Profitability:**

| Quarter      | Equity    | ROE    |
|--------------|-----------|--------|
| 2025-09-30   | $16.93B  | 4.16%  |
| 2025-06-30   | $17.85B  | 3.69%  |
| 2025-03-31   | $17.11B  | 4.08%  |
| 2024-12-31   | $16.43B  | 4.17%  |
| 2024-09-30   | $15.58B  | 3.63%  |

    *   **Analysis:** Equity has fluctuated. ROE (Return on Equity) is relatively stable, although a bit low compared to its historical values.

**7) Comprehensive Analysis (Summary)**

Overall, the analysis paints a mixed picture of Intuitive Surgical (ISRG).

*   **Strengths:**
    *   Strong revenue and earnings growth in recent quarters.
    *   High and stable profit margins.
    *   Analyst target prices suggest potential upside (but with wide divergence).
    *   High MRI indicator
    *   Hybrid signal suggests buying position.

*   **Weaknesses:**
    *   Underperformance compared to the S&P 500.
    *   High volatility (Beta above 1) and significant historical drawdowns.
    *   Negative Alpha in recent periods.
    *   Recent price weakness and a short-term declining trend.
    *   0% expected return.
    *   Equity fluctuates
    *   Recent ratings decline

*   **Considerations:**
    *   The medical technology sector is subject to regulatory changes and technological advancements.
    *   The high cost of Intuitive Surgical's systems could be a barrier to entry for some hospitals, but also provides ISRG with a strong moat as hospitals are stickier to the company once they adopt the platform.
    *   News is mixed, but recent headlines are somewhat cautious.

*   **Conclusion:** While ISRG shows promising growth in revenue and earnings, its recent underperformance, high volatility, negative alpha, and neutral ROE/RSI indicators warrant caution. Potential investors should carefully weigh the company's strengths against its weaknesses and consider their risk tolerance and investment horizon. The current MRI and Hybrid signal point towards investment opportunities, but the stock shows a short-term declining trend.


**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.